Patients with central nervous system (CNS) disease are not eligible
AML patients with active central nervous system (CNS) disease will be excluded.
Active extramedullary AML in testes or central nervous system (CNS)
Non-central nervous system (CNS) radiotherapy within  week prior to CD of study therapy
History or evidence of uncontrollable central nervous system (CNS) disease
Subject has known current central nervous system (CNS) disease
Presence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal)
History of central nervous system (CNS) disease is acceptable if effectively treated and demonstrated stable disease for >=  months from protocol tissue procurement
Active central nervous system (CNS) disease at time of screening.
Patients with primary central nervous system (CNS) cancer.
Active central nervous system (CNS) disease.
Central nervous system (CNS) tumors
Central nervous system (CNS) disease
Active extramedullary AML in testes or central nervous system (CNS)
Patients with retinoblastoma protein (Rb) positive recurrent, progressive or refractory central nervous system (CNS) tumors
Uncontrolled metastatic disease to the brain or central nervous system (CNS).
Presence of central nervous system (CNS) disease, which is symptomatic
TREATMENT WITH SJCAR: Central nervous system (CNS)- disease with or without neurologic changes
Adequate central nervous system (CNS) function defined as:\r\n* Patients with seizure disorder may be enrolled if on allowed anti-convulsants and well controlled; benzodiazepines and gabapentin are acceptable\r\n* CNS toxicity < grade 
Patients must not have evidence of active central nervous system (CNS) disease
Active central nervous system (CNS) or extramedullary disease
Subjects with symptomatic central nervous system (CNS) disease which is not adequately controlled
Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
Have central nervous system disease (CNS) as follows:
Active central nervous system (CNS) disease
Patients with a history of central nervous system disease must have no clinical or radiological evidence of central nervous system (CNS) disease at the time of protocol enrollment and with CNS toxicity =< grade ; patients with seizure disorders may be enrolled if seizures are well controlled
Presence of active and clinically relevant central nervous system (CNS) disorder;
Presence of active and clinically relevant Central Nervous System (CNS) disorder
(Bevacizumab-related exclusion) History or evidence upon physical/neurological examination of central nervous system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy
Active central nervous system (CNS) disorder or seizure disorder or known CNS disease or neurologic symptomatology
Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance;
Active central nervous system (CNS) disease in patient with history of CNS malignancy.
Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI)
Active, uncontrolled central nervous system (CNS) disease
Active central nervous system (CNS) malignancy
Patients with history of central nervous system (CNS) lymphoma can be enrolled if the CNS disease has been controlled with therapy for a minimum of  weeks; brain magnetic resonance imaging (MRI) is not required for eligibility
Eligible for extra-central nervous system (CNS) SAbR to - sites of disease
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Patients with clinical evidences of active central nervous system (CNS) disease at inclusion
Active central nervous system (CNS) disease
Patients with >=  white blood cells in the cerebrospinal fluid with blasts (CNS) disease will be eligible if central nervous system (CNS) disease is responsive to therapy
Patient with active central nervous system (CNS) disease
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least  weeks after therapy
Participant has overt central nervous system (CNS) disease (CNS  status)
Patients with a history of central nervous system disease must not have severe peripheral neuropathy, signs of leukencephalopathy, or active central nervous system (CNS) infection; patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy
Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
Patients with active central nervous system (CNS) or epidural tumor
Patients with central nervous system (CNS) disease who have received treatment and disease has been stable for four weeks are eligible
Active central nervous system (CNS) or extramedullary disease
Active central nervous system (CNS) disease.
Patients with central nervous system (CNS) tumors who are receiving steroids are eligible
Non-central nervous system (CNS) radiotherapy within  week prior to CD of study therapy
No active central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease
Patients may NOT have evidence or symptoms of central nervous system (CNS) disease at the time of enrollment
Known chronic or active viral infections of the central nervous system (CNS)
Confirmed absence of central nervous system (CNS) disease
Active central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease
Prior history of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease
Patients with active central nervous system (CNS) or epidural tumor
Patients with central nervous system (CNS) disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapy
History of primary central nervous system (CNS) disease that would interfere with subject evaluation
Patients who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible
Patient with active central nervous system (CNS) disease
No current central nervous system (CNS) myeloma at time of enrollment
Tumors arising outside of the central nervous system (CNS)
Presence of central nervous system (CNS) disease
Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
Patients with central nervous system (CNS) malignancies.
Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease.
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy)
Active central nervous system (CNS) disease
Who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible
Active leukemic central nervous system (CNS) disease
Eligible for extra-central nervous system (CNS) SABR to - sites of disease
Patients with active or untreated central nervous system (CNS) disease; patients previously treated for CNS disease must be asymptomatic and must not be using steroids for at least  weeks prior to starting the study treatment
Subject has known current central nervous system (CNS) disease
Pre-existing central nervous system (CNS) demyelination or seizure disorders
Central nervous system (CNS) toxicity =< grade 
Patients with active central nervous system (CNS) malignancy
Central nervous system (CNS) function defined as:\r\n* Patients with seizure disorder may be enrolled if on allowed anti-convulsants and well controlled; benzodiazepines and gabapentin are acceptable\r\n* CNS toxicity =< grade 
Patient has chronic or active viral infections of the central nervous system (CNS)
Patients with disease progression in the central nervous system (CNS) only
Known active central nervous system (CNS) leukemia or lymphoma  patients with previously treated CNS disease are permitted if neurologically stable with no ongoing or anticipated need for steroid therapy are eligible
Patients with active central nervous system (CNS) or epidural tumor
History of central nervous system (CNS) disease
Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
Primary disease involving the Central Nervous System (CNS)
Symptomatic leukoencephalopathy, active central nervous system (CNS) malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
Have symptomatic or non stable central nervous system (CNS) malignancy.
History of or active central nervous system (CNS) malignancy
Active/symptoms of central nervous system (CNS) disease
Evidence for central nervous system (CNS) metastatic disease
History or evidence upon physical/neurological examination of central nervous system (CNS) disease unrelated to cancer, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures)
Patient has active or history of central nervous system (CNS) disease
Adequate central nervous system function defined as:\r\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\r\n* CNS toxicity =< grade 
Active central nervous system (CNS) disease at the time of treatment
Active central nervous system (CNS) or symptomatic epidural metastatic disease
History of central nervous system (CNS) lymphoma or other CNS disease
No active central nervous system (CNS) disease
Known central nervous system (CNS) disease
Patients with known active central nervous system (CNS) disease
History of central nervous system (CNS) thrombotic/embolic or ischemic event(s)
Symptomatic central nervous system (CNS) NHL.
Symptomatic central nervous system (CNS) disease.
Known active central nervous system (CNS) malignancy
Known history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease).
Hematologic and primary central nervous system (CNS) malignancies
Any primary or active central nervous system (CNS) malignancy, including metastatic disease
Presence of central nervous system (CNS) metastatic disease
Active central nervous system (CNS) disease
Patients with stable, treated central nervous system (CNS) disease are eligible
Have active Central Nervous System (CNS) disease
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Central Nervous System (CNS) disease only.
Active central nervous system (CNS) disease
Active central nervous system (CNS) or extramedullary malignant disease
Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy
Patients with central nervous system (CNS) disease or testicular disease are eligible
Uncontrolled central nervous system (CNS) disease
Known central nervous system (CNS) disease
Patients with active central nervous system (CNS) malignancy are not eligible for this trial
Active/symptoms of central nervous system (CNS) disease
Central nervous system (CNS) disease
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Patients with documented central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease
Patients with a history of central nervous system (CNS) malignancy.
Symptomatic or untreated central nervous system (CNS) metastatic disease. Patients with previously treated CNS metastatic disease which has been stable for at least  days are eligible
Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting
Patient has active or history of central nervous system (CNS) disease.
History of central nervous system (CNS) PTLD
Active Central Nervous System [CNS] disease
Active central nervous system (CNS) disease
b. Central nervous system (CNS) trauma or active seizure disorders requiring medication
Patients with active central nervous system (CNS) disease
Pre-existing central nervous system (CNS) demyelination or seizure disorders
Active MM involving the central nervous system (CNS).
Active central nervous system (CNS) disease (related to primary malignancy) at the time of enrollment
History of significant central nervous system (CNS) injury or disease predating or unrelated to cancer diagnosis
Patient has symptomatic primary or metastatic central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy
Patients with history of seizures or uncontrolled central nervous system (CNS) disease, significant hepatic or renal dysfunction
Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
History of central nervous system (CNS) tumor
Cranial radiotherapy for central nervous system (CNS) leukostasis;
History of Grade >=  central nervous system (CNS) hemorrhage
All patients need to have received at least one prior central nervous system (CNS) directed therapy; there is no restriction on the number of recurrences
Participant is currently receiving treatment with benzodiazepines or other central nervous system (CNS) depressants
Active central nervous system (CNS) disease
History of central nervous system (CNS) disease, CNS radiation, intrathecal therapy, or CNS surgery
Active central nervous system (CNS) disease (the action for acupuncture may be associated with central nervous system activity, and patients with CNS pathology may respond differently to treatment than the general population)
Exclusion criteria include previous central nervous system (CNS) radiation or CNS tumors that in the judgment of the investigators are likely to undergo progression during or shortly after radiotherapy
Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
Non-central nervous system (CNS) malignant disease must be sufficiently controlled so that patient can be without additional systemic therapy for approximately  months
Central nervous system (CNS) only disease on recent imaging
Patients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic.
Suspected central nervous system (CNS) tumor(s) or sarcoma.
